38
Participants
Start Date
September 29, 2021
Primary Completion Date
December 1, 2025
Study Completion Date
December 1, 2029
Nab-paclitaxel
"1. Patients will receive treatment Day 1 and Day 15 of each cycle (28 days).~2. Nab-paclitaxel (80 mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle).~3. Other Name: Abraxane"
Gemcitabine
"1. Patients will receive treatment Day 1 and Day 15 of each cycle (28 days).~2. Gemcitabine (500mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle).~3. Other Name: Gemzar"
Cisplatin
"1. Patients will receive treatment Day 1 and Day 15 of each cycle (28 days).~2. Cisplatin (20mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle).~3. Other Name: N/A"
Irinotecan
"1. Patients will receive treatment Day 1 and Day 15 of each cycle (28 days).~2. Irinotecan (20 mg/m2) will be administered IV on Day 1 and Day 15 (28 day cycle).~3. Other Name: N/A"
Capecitabine
"1. Patients will receive treatment Day 1-7 and Day 15-21 of each cycle (28 days).~2. Capecitabine (500 mg) will be administered orally twice a day on days 1-7 and 15-21 of each cycle (28 days).~3. Other Name: Xeloda"
Pembrolizumab
"1. Patients will receive treatment Day 1 every other cycle (every 6 weeks) (28 days) during maintenance phase.~2. Pembrolizumab (400 mg) will be administered IV on day 1 every other cycle (every 6 weeks).~3. Other Name: MK-3475; Keytruda"
Olaparib
"1. Patients will receive treatment on Days 1-21 during the maintenance phase.~2. Olaparib (300 mg) will be administered orally twice a day on Days 1- 21 of each cycle (28 days).~3. Other Name: Lynparza"
RECRUITING
Sidney Kimmel Comprehensive Cancer Center, Baltimore
Merck Sharp & Dohme LLC
INDUSTRY
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
OTHER